Archive


Category: AAV

  • 2nd Gene Therapy Immunogenicity

    The 2nd Gene Therapy Immunogenicity Summit is the industry’s definitive forum enabling you to better modulate, measure and predict immune response to your gene therapy candidate. In the context of ever-increasing gene therapy clinical activity and uncertainty around immunogenicity challenges, the Gene Therapy Immunogenicity Summit will unite large pharma and innovative biotechs to ensure that you’re up to speed on […]

  • ‘Knowledge is power’ for rare diseases and NAbs

    Cure Rare Disease’s Rich Horgan discusses the importance of preclinical NAbs screening and helping rare disease patients better understand their eligibility for gene therapies. Neutralising antibodies (NAbs) present a unique challenge to researchers looking to treat patients with AAV treatment. As AAV is a virus derived from the common cold, the immune system can easily […]

  • Bayer paying up to $4B for gene therapy pioneer AskBio

    The deal, offering $2 billion up front and $2 billion in future milestone payments, includes a gene therapy manufacturing facility and a pipeline that includes treatments for Parkinson’s and congestive heart failure.